Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 19;10(8):1777.
doi: 10.3390/jcm10081777.

Bone Metastases from Gastric Cancer: What We Know and How to Deal with Them

Angelica Petrillo  1   2 , Emilio Francesco Giunta  1   2 , Annalisa Pappalardo  1   2 , Davide Bosso  1 , Laura Attademo  1 , Cinzia Cardalesi  1 , Anna Diana  1   2 , Antonietta Fabbrocini  1 , Teresa Fabozzi  1 , Pasqualina Giordano  1 , Margaret Ottaviano  1   3   4 , Mario Rosanova  1 , Antonia Silvestri  1 , Piera Federico  1 , Bruno Daniele  1
Affiliations
Review

Bone Metastases from Gastric Cancer: What We Know and How to Deal with Them

Angelica Petrillo et al. J Clin Med. .

Abstract

Gastric cancer (GC) is the third cause of cancer-related death worldwide; the prognosis is poor especially in the case of metastatic disease. Liver, lymph nodes, peritoneum, and lung are the most frequent sites of metastases from GC; however, bone metastases from GC have been reported in the literature. Nevertheless, it is unclear how the metastatic sites may affect the prognosis. In particular, knowledge about the impact of bone metastases on GC patients' outcome is scant, and this may be related to the rarity of bone lesions and/or their underestimation at the time of diagnosis. In fact, there is still a lack of specific recommendation for their detection at the diagnosis. Then, the majority of the evidences in this field came from retrospective analysis on very heterogeneous study populations. In this context, the aim of this narrative review is to delineate an overview about the evidences existing about bone metastases in GC patients, focusing on their incidence and biology, the prognostic role of bone involvement, and their possible implication in the treatment choice.

Keywords: RANK-L; bone flare; metastatic gastric cancer; stage IV; target therapy; treatment.

PubMed Disclaimer

Conflict of interest statement

Angelica Petrillo received personal fee from Eli-Lilly, Servier and MSD; EFG had personal fees from Novartis; L.A. received personal fee from GSK; A.D. received personal fees from Roche, Gentili, Italfarmaco, Ipsen, Novartis; B.D. received personal fee from Ipsen, Eisai, Eli Lilly, Astra Zeneca, Sanofi, MSD, Bayer, Roche, Amgen. No fees are connected with the submitted paper. The other authors declare no conflict of interest. The funders had no role in the design, writing of the manuscript, or in the decision to publish the paper.

Figures

Figure 1
Figure 1
Incidence of bone metastases from gastric cancer according to skeletal sites.
See this image and copyright information in PMC

References

    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Surveillance, Epidemiology, and End Results (SEER) Database. [(accessed on 19 December 2020)]; Available online: https://seer.cancer.gov/statfacts/html/stomach.html.
    1. Smyth E.C., Verheij M., Allum W., Cunningham D., Cervantes A., Arnold D., ESMO Guidelines Committee Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2016;27(Suppl. S5):v38–v49. doi: 10.1093/annonc/mdw350. - DOI - PubMed
    1. Tirino G., Pompella L., Petrillo A., Laterza M.M., Pappalardo A., Caterino M., Orditura M., Ciardiello F., Galizia G., De Vita F. What’s New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future Perspectives. Int. J. Mol. Sci. 2018;19:2659. doi: 10.3390/ijms19092659. - DOI - PMC - PubMed
    1. Gambardella V., Fleitas T., Tarazona N., Papaccio F., Huerta M., Roselló S., Gimeno-Valiente F., Roda D., Cervantes A. Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress. J. Clin. Med. 2020;9:3049. doi: 10.3390/jcm9093049. - DOI - PMC - PubMed

LinkOut - more resources